Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
Find the Effect of Web-based Entertainment on Society: Exploring the Computerized Scene - 2Glamour Shots once ruled the mall. I went to one of the last ones standing.
- 3U.S. overhauls childhood vaccine schedule, recommends fewer shots
- 4Surprising links between autism, Alzheimer’s could change how we treat both
- 5Dinosaur collagen used to create one-of-a-kind handbag
- Artemis 2 astronauts head for the moon after make-or-break engine burn (video)
- Anger as German family business group opens talks with far-right AfD
- Bother Control Administrations for 2024: Decide for Your Home
- From Fledgling to Master: Self-awareness in a Side interest
- 'Heated Rivalry's Ilya Rozanov is now a queer icon in Russia
- Find the Standards of Viable Refereeing: Settling Debates with Strategy
- Artemis 2 astronauts — now halfway to the moon — report 'burning smell' from toilet, but everything's fine
- Timothy Busfield turns himself in to face child sexual abuse charges in New Mexico
- Elite Execution Gaming PCs for Gamers
